Product Information
DULOXETINE HCL DR 30 MG CAP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1024 per EA under NDC 68180029506. Its NADAC has been published 659 times since Feb 19, 2014.
FDA first approved this application on Dec 11, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180029506
Classification
Generic
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DULOXETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090694FDA Approved
12/11/2013
TE Code
AB
On Market Since
12/11/2013
Pharmacological Classes
Price Statistics
The NADAC for DULOXETINE HCL DR 30 MG CAP has been published 659 times since Feb 19, 2014, and over the history we have for it it has declined 98.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1024 per EA |
|---|---|
| All-time high | $6.0216 (Mar 12, 2014) |
| All-time low | $0.0696 (May 22, 2024) |
| 52-week high | $0.1058 |
| 52-week low | $0.0781 |
| Median price | $0.1518 |
| Average price | $0.4765 |
| Largest weekly change | -55.4% (Sep 17, 2014) |
| Weeks tracked | 659 |
| Tracking since | Feb 19, 2014 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 24% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Duloxetine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DULOXETINE HCL DR 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DULOXETINE HCL DR 30 MG CAP, manufactured by Lupin Pharmaceuticals Inc., is $0.1024 per EA (NDC 68180029506), effective Sep 30, 2026.
How has the price of DULOXETINE HCL DR 30 MG CAP changed over time?
Over the history we have for it, the NADAC for DULOXETINE HCL DR 30 MG CAP has declined 98.3%. It has been tracked across 659 weekly CMS publications since Feb 19, 2014.
What are the highest and lowest recorded NADAC prices for DULOXETINE HCL DR 30 MG CAP?
Since Feb 19, 2014, the NADAC for DULOXETINE HCL DR 30 MG CAP has ranged from a low of $0.0696 (May 22, 2024) to a high of $6.0216 (Mar 12, 2014), with a median of $0.1518 per EA.
Are there cheaper alternatives to DULOXETINE HCL DR 30 MG CAP?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DULOXETINE HCL DR 30 MG CAP, is $0.0782 per EA — about 24% below DULOXETINE HCL DR 30 MG CAP.
Who manufactures DULOXETINE HCL DR 30 MG CAP?
DULOXETINE HCL DR 30 MG CAP (NDC 68180029506) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.